P1161 PERI-TRANSPLANT TREATMENT WITH ANTI-HCV E2 HUMAN MONOCLONAL ANTIBODY MBL-HCV1 IN COMBINATION WITH A PROTEASE INHIBITOR RESULTS IN UNDETECTABLE HCVRNA IN THE EARLY POST-TRANSPLANT PERIOD

Background and Aims: 54% of prison Chronic Hepatitis C (HCV) services in England are local hospital in-reach (1). Can these services offer comparable outcomes compared with a District General Hospital (DGH) outpatients service? Aims of audit were to compare care and treatment outcomes, identify differences and implement change to ensure equitable care in the prison setting. (1) National survey of HCV services in prisons in England, DOH, 2012. Methods: Retrospective audit analysis of service databases for four year of treatment (anti-viral therapy) since prison in-reach service commencement in 2009 and care outcomes for 2012. Both services offered weekly clinics (covering 4 male prisons) and undertaken by one senior specialist nurse. Results: Care outcomes: Comparable patient groups, clinics held, numbers seen and genotype splits. Care outcomes comparable except that more prison patients were assessed but not treated, fewer prisoners received treatment with the majority being treatment naive. Treatment outcome: Comparable group, naive, treatment experienced and genotype splits. Fewer prisoners received treatment but sustained virological response rate (SVR) rates were comparable. The prison cohort was reduced due to loss to follow-up with lack of SVR data. Conclusions: Nurse led in-reach HCV prison services can deliver comparable outcomes including SVR’s compared to DGH services. More patients in the prison setting need to be treated. Since this audit we have implemented a one-stop pre treatment investigations hospital visit for prisoners and ensure results are forwarded to the next care provider when prisoners are transferred or released. These changes should increase the numbers treated in the future.